Personalis presents ultrasensitive cancer relapse detection data at ASCO
Personalis (NASDAQ:PSNL) unveiled comprehensive clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, establishing the diagnostic capabilities of its ultrasensitive minimal residual disease (MRD) detection platform.



_1412480_640x360_2502167619691-640x360.webp&w=3840&q=75)







